StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Madrigal Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$321.10M. For fiscal 2025 it was -$298.59M. The highest annual figure on record is $81.77M in fiscal 2009.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$298.59M–
FY2024Dec 31, 2024-$496.78M–
FY2023Dec 31, 2023-$379.97M–
FY2022Dec 31, 2022-$293.10M–
FY2021Dec 31, 2021-$242.08M–
FY2020Dec 31, 2020-$206.20M–
FY2019Dec 31, 2019-$94.86M–
FY2018Dec 31, 2018-$40.59M–
FY2017Dec 31, 2017-$31.99M–
FY2016Dec 31, 2016-$25.22M–
FY2015Dec 31, 2015-$2.57M–
FY2014Dec 31, 2014-$83.28M–
FY2013Dec 31, 2013-$87.04M–
FY2012Dec 31, 2012-$60.20M–
FY2011Dec 31, 2011-$43.97M–
FY2010Dec 31, 2010-$34.97M-142.8%
FY2009Dec 31, 2009$81.77M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$55.93M–
Q1 FY2026Mar 31, 2026-$92.34M–
Q4 FY2025Dec 31, 2025-$59.22M–
Q3 FY2025Sep 30, 2025-$113.62M–
Q2 FY2025Jun 30, 2025-$46.83M–
Q1 FY2025Mar 31, 2025-$78.93M–
Q4 FY2024Dec 31, 2024-$66.63M–
Q3 FY2024Sep 30, 2024-$116.01M–
Q2 FY2024Jun 30, 2024-$162.27M–
Q1 FY2024Mar 31, 2024-$151.87M–
Q4 FY2023Dec 31, 2023-$117.03M–
Q3 FY2023Sep 30, 2023-$98.40M–
Q2 FY2023Jun 30, 2023-$86.32M–
Q1 FY2023Mar 31, 2023-$78.21M–
Q4 FY2022Dec 31, 2022-$85.17M–
Q3 FY2022Sep 30, 2022-$80.29M–
Q2 FY2022Jun 30, 2022-$70.16M–
Q1 FY2022Mar 31, 2022-$57.48M–
Q4 FY2021Dec 31, 2021-$64.50M–
Q3 FY2021Sep 30, 2021-$63.06M–
Q2 FY2021Jun 30, 2021-$61.65M–
Q1 FY2021Mar 31, 2021-$52.87M–
Q4 FY2020Dec 31, 2020-$59.44M–
Q3 FY2020Sep 30, 2020-$58.67M–
Q2 FY2020Jun 30, 2020-$50.21M–
Q1 FY2020Mar 31, 2020-$37.88M–
Q4 FY2019Dec 31, 2019-$29.93M–
Q3 FY2019Sep 30, 2019-$24.17M–
Q2 FY2019Jun 30, 2019-$22.68M–
Q1 FY2019Mar 31, 2019-$18.09M–
Q4 FY2018Dec 31, 2018-$14.43M–
Q3 FY2018Sep 30, 2018-$11.31M–
Q2 FY2018Jun 30, 2018-$7.80M–
Q1 FY2018Mar 31, 2018-$7.05M–
Q4 FY2017Dec 31, 2017-$8.85M–
Q3 FY2017Sep 30, 2017-$8.63M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?